Skip to content

pharmacogenomics of Azathioprine induced myelosuppression in the treatment of Pemphigus Vulgaris--study of mutation in TPMT*3 and NUDT15 gene in Chinese people and changes in blood configuration(hemogram).

pharmacogenomics of Azathioprine induced myelosuppression in the treatment of Pemphigus Vulgaris--study of mutation in TPMT*3 and NUDT15 gene in Chinese people and changes in blood configuration(hemogram).

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OIC-17011759
Enrollment
Unknown
Registered
2017-06-26
Start date
2016-08-01
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pemphigus Vulgaris

Interventions

Case series:Azathioprine

Sponsors

Dermatological Department, West China hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years (exclude 65 years), include both gender; 2. The patients were diagnosed as Pemphigus Vulgaris based on clinical manifestation,histopathology,immune pathology and detection of specific antibodies by ELISA; 3. Volunteer to participate in this project and be able to follow the requirement; 4. Signed formed consent ,and be able to follow according to the requirement.

Exclusion criteria

Exclusion criteria: (1) The patients with severe cardiac,pulmonary,liver,renal,nervous or mental disease; (2) The patients with history of AZA allergy or allergy of any kind; (3) The patient with definite evidence of having infection or metastatic tumor; (4) The patient having history or clinical tests that shows complicated hematological disease,particularly leukocytopenia; (5) Pregnant women,lactating mother and women of child-bearing age who are planning to get pregnant; (6) The patient who is unable to co-operate or cannot adhere to treatment or predicted to have a poor compliance.

Design outcomes

Primary

MeasureTime frame
blood test;

Secondary

MeasureTime frame
liver function;kidney function;

Countries

China

Contacts

Public ContactWei Li

Dermatological Department, West China hospital, Sichuan University

liwei@mcwcums.com+86 18980601695

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026